This approval was based on results from the phase 3 BOREAS (NCT03930732) and NOTUS (NCT04456673) trials, which demonstrated that dupilumab can significantly reduce COPD exacerbations. 2 The first ...

Arguably the most buzzed about advancement in the COPD treatment landscape is the emergence of new biologic therapies ... “When you take that diseased part out, that helps to restore the lung’s ...

Dry halotherapy is associated with natural or artificial salt ... means it cannot yet be considered a proven treatment for conditions like asthma, COPD, or skin conditions. Before trying a salt ...

Smoking is the most common aetiologic factor. Evidence for the treatment of patients with mild-to-moderate COPD is limited. Here, the authors show that long-term treatment with high-dose N ...

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD ...

Advancements in Diagnostic Technologies and Treatments: Development of technological advancement is one of the key factors enhancing the growth of the COPD diagnosis and treatment industry.

After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer ...

Dupixent is an “add-on” drug for COPD, meaning patients take it in addition to inhaled medication Dupixent isn’t approved as a stand-alone treatment for COPD. The U.S. Food and Drug ...

With the label expansion, Dupixent becomes the first biologic treatment for COPD patients in the U.S. The IL-4 and IL-13 inhibitor is approved to be used as an add-on maintenance treatment by ...

Dupixent becomes the first-ever targeted therapy for patients with COPD, the first biologic for the disease, and the first new treatment approach in Europe in over a decade. It has been cleared ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

For these patients, dupilumab is a welcome addition to the COPD-treatment armamentarium, he said. The approval was based on data from a pair of phase 3 studies known as BOREAS and NOTUS.